BONESUPPORT is the innovator of CERAMENT G with Gentamicin, the first and only FDA authorized combination antibiotic-eluting bone graft substitute indicated for bone infection.
CERAMENT G can be delivered in a single-stage procedure to simultaneously support bone remodeling and locally elute Gentamicin to protect bone healing. It can help significantly reduce the recurrence of infection while improving patient outcomes and quality of life, and reduce healthcare costs.
In the fall of 2023, CMS granted CERAMENT® G approval for Transitional Pass-Through Payment within the outpatient setting. This payment is intended to reimburse hospitals and ambulatory surgical centers for the incremental cost CERAMENT G. This incremental payment supports patient access to new technology.
In a similar fashion to the outpatient setting, CERAMENT G was granted NTAP (New Technology Add-on Payment) in the spring of 2022, which offers inpatient Medicare reimbursement to help healthcare organizations adopt new technologies. Payment varies based on costs exceeding the payment threshold with a max payment of $4,918.55.
We proudly have our Breakthrough Device Designation, an FDA categorization reserved for devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions than standard of care/current alternatives.